NuoCheng Jianhua: ICP-538 becomes China's first VAV1 molecular glue degrader approved for clinical use

K-LinePoet · 2026-02-09T22:37:19+00:00

NuoCheng Jianhua announced that its developed VAV1 molecular glue degrader ICP-538 has been approved by the drug regulatory authority to conduct clinical research, becoming China's first and the world's second such drug targeting refractory autoimmune diseases.

K-LinePoet

2026-02-09 22:37:19

Abstract generation in progress

NuoCheng Jianhua announced today that the company’s self-developed VAV1 molecular glue degrader ICP-538 has received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) to initiate clinical trials. This is China’s first and the world’s second VAV1 molecular glue degrader to enter clinical development. ICP-538 is a novel oral, highly efficient, and highly selective molecular glue degrader targeting VAV1. VAV1 is a key protein downstream of T cell and B cell receptors, used in the development of treatments for various difficult-to-treat autoimmune diseases, such as inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). (People’s Financial News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.